Emergent BioSolutions (EBS) announced that the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Announces Board Member Retirement
- Emergent BioSolutions: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Emergent BioSolutions’ Earnings Call Highlights Strong Growth
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Emergent BioSolutions Reports Strong Q3 2025 Results